Acid Ceramidase Inhibitor IV 1PC X 10MG

Biochem/physiol Actions

Target IC₅₀: 79 nM against HEK293 lysosomal lysate AC activity

Reversible: no

Primary TargetAcid ceramidase

Cell permeable: yes

General description

A cell-permeable, chemically and metabolically stable (t_1/2 >5 h in aqueous buffers at pH 4.5 and 7.4; t_1/2 >2 h in murine plasma at 37 °C) benzoxazolone carboxamide (BOC) compound that inhibits acid ceramidase (AC) activity in a potent (IC₅₀ = 79 nM against HEK293 lysosomal lysate AC activity) and selective manner via covalent modification of the active site Cys143, exhibiting little or no potency toward a panel of 15 enzymes, including proteases, lipoxygenases, cyclooxygenases, sPLA₂, and monoacylglycerol lipase (67% inhibition of cathepsin D and ≤17.1% inhibition of the rest at 10 µM). Culture treatment results in long-lasting (>6 h) suppression of cellular AC activity in murine macrophage-like Raw 264.7 and human colon adenocarcinoma SW403 cells (IC₅₀ with 3 h treatment = 400 and 825 nM, respectively), as well as built-ups of cellular AC substrates Cer(d18:0/16:0) & Cer(d18:1/16:0) in a dose-dependent manner. Intraperitoneal injection (10 mg/kg) effectively inhibits tissue AC activity in multiple organs, including lung, heart, kidney, brain hippocampus, and liver (by 70%, 60%, 44%, 40%, 35%, respectively), with good pharmacokinetic properties (T_max = 30 min, C_max = 1.768 µg/mL, t_1/2 = 458 min, AUC_{0-8 h} = 0.31 mg⋅min/mL; 10 mg/kg i.p.).

Acid Ceramidase Inhibitor, BOC, CAS 1644158-57-5, is a cell-permeable, potent inhibitor of acid ceramidase (IC₅₀ = 79 nM against HEK293 lysosomal lysate AC activity).

A cell-permeable, chemically and metabolically stable (t_1/2 >5 h in aqueous buffers at pH 4.5 and 7.4; t_1/2 >2 h in murine plasma at 37 °C) benzoxazolone carboxamide (BOC) compound that inhibits acid ceramidase (AC) activity in a potent (IC₅₀ = 79 nM against HEK293 lysosomal lysate AC activity) and selective manner via covalent modification of the active site Cys143, exhibiting little or no potency toward a panel of 15 enzymes, including proteases, lipoxygenases, cyclooxygenases, sPLA₂, and monoacylglycerol lipase (67% inhibition of cathepsin D and ≤17.1% inhibition of the rest at 10 µM). Culture treatment results in long-lasting (>6 h) suppression of cellular AC activity in murine macrophage-like Raw 264.7 and human colon adenocarcinoma SW403 cells (IC₅₀ with 3 h treatment = 400 and 825 nM, respectively), as well as built-ups of cellular AC substrates Cer(d18:0/16:0) & Cer(d18:1/16:0) in a dose-dependent manner. Intraperitoneal injection (10 mg/kg) effectively inhibits tissue AC activity in multiple organs, including lung, heart, kidney, brain hippocampus, and liver (by 70%, 60%, 44%, 40%, 35%, respectively), with good pharmacokinetic properties (T_max = 30 min, C_max = 1.768 µg/mL, t_1/2 = 458 min, AUC_{0-8 h} = 0.31 mg⋅min/mL; 10 mg/kg i.p.).Please note that the molecular weight for this compound is batch-specific due to variable water content. Please refer to the vial label or the certificate of analysis for the batch-specific molecular weight. The molecular weight provided represents the baseline molecular weight without water.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Pizzirani, D., et al. 2015. Angew. Chem. Int. Ed. Engl.54, 485.

Packaging

10 mg in Glass bottle

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Warning

Toxicity: Standard Handling (A)